Recursion Pharmaceuticals (NASDAQ:RXRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Recursion Pharmaceuticals (NASDAQ:RXRX) from a strong sell rating to a hold rating in a research report released on Saturday.

A number of other analysts also recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, February 26th. Morgan Stanley set a $11.00 price target on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Bank of America dropped their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Finally, UBS Group set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Trading Down 1.1%

NASDAQ:RXRX opened at $3.63 on Friday. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a 1-year low of $2.98 and a 1-year high of $7.89. The firm has a market capitalization of $1.89 billion, a price-to-earnings ratio of -2.45 and a beta of 0.97. The business’s 50-day moving average price is $4.16 and its two-hundred day moving average price is $4.67.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The business had revenue of $35.54 million for the quarter, compared to the consensus estimate of $24.56 million. During the same quarter last year, the business posted ($0.53) EPS. The firm’s revenue was up 671.7% compared to the same quarter last year. On average, equities analysts expect that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Ben R. Taylor sold 21,383 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $4.18, for a total value of $89,380.94. Following the sale, the chief financial officer owned 761,550 shares in the company, valued at $3,183,279. This trade represents a 2.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Blake Borgeson sold 220,000 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $4.20, for a total value of $924,000.00. Following the completion of the transaction, the director owned 6,429,863 shares of the company’s stock, valued at $27,005,424.60. This represents a 3.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 599,212 shares of company stock valued at $2,562,550 over the last quarter. 8.43% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in RXRX. Norges Bank bought a new position in Recursion Pharmaceuticals during the second quarter valued at about $16,040,000. Bank Pictet & Cie Europe AG bought a new stake in Recursion Pharmaceuticals in the third quarter worth about $7,954,000. Vanguard Group Inc. boosted its stake in Recursion Pharmaceuticals by 10.3% in the third quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock valued at $194,127,000 after acquiring an additional 3,708,975 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in Recursion Pharmaceuticals by 94.8% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 1,774,995 shares of the company’s stock valued at $8,662,000 after purchasing an additional 863,910 shares during the period. Finally, Ethic Inc. bought a new stake in shares of Recursion Pharmaceuticals in the second quarter valued at $107,000. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.